CN113171468A - 一种全过程靶向分子及其在构建递药系统中的应用 - Google Patents

一种全过程靶向分子及其在构建递药系统中的应用 Download PDF

Info

Publication number
CN113171468A
CN113171468A CN202011548622.XA CN202011548622A CN113171468A CN 113171468 A CN113171468 A CN 113171468A CN 202011548622 A CN202011548622 A CN 202011548622A CN 113171468 A CN113171468 A CN 113171468A
Authority
CN
China
Prior art keywords
targeting molecule
tumor
molecule
polypeptide
vap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011548622.XA
Other languages
English (en)
Chinese (zh)
Inventor
陆伟跃
周建芬
柴芝兰
吴荪奕
谢操
王浩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fudan University
Original Assignee
Fudan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fudan University filed Critical Fudan University
Publication of CN113171468A publication Critical patent/CN113171468A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biochemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202011548622.XA 2020-01-23 2020-12-24 一种全过程靶向分子及其在构建递药系统中的应用 Pending CN113171468A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020100781533 2020-01-23
CN202010078153 2020-01-23

Publications (1)

Publication Number Publication Date
CN113171468A true CN113171468A (zh) 2021-07-27

Family

ID=76921568

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202011548622.XA Pending CN113171468A (zh) 2020-01-23 2020-12-24 一种全过程靶向分子及其在构建递药系统中的应用
CN202180008713.0A Pending CN114981310A (zh) 2020-01-23 2021-01-20 一种全过程靶向分子及其药物复合物在构建递药系统中的应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202180008713.0A Pending CN114981310A (zh) 2020-01-23 2021-01-20 一种全过程靶向分子及其药物复合物在构建递药系统中的应用

Country Status (2)

Country Link
CN (2) CN113171468A (fr)
WO (1) WO2021147917A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115825442A (zh) * 2021-11-23 2023-03-21 中国人民解放军总医院第一医学中心 钙钛矿纳米晶在制备用于肿瘤诊断或治疗的探针中的应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114522245B (zh) * 2022-03-04 2024-06-18 宿州学院 一种靶向端粒酶纳米药物递送系统及其制备方法与应用
CN114806546B (zh) * 2022-05-18 2024-07-12 南京大学 基于荧光分子的有机框架材料及其制备方法和应用
CN115006368B (zh) * 2022-07-01 2023-03-14 重庆大学 细胞膜包被纳米药物及其应用
CN115919766B (zh) * 2022-12-27 2023-10-24 国科宁波生命与健康产业研究院 一种复合纳米胶束及其制备方法和应用
CN117482044B (zh) * 2023-11-13 2024-09-20 湛江中心人民医院 负载pd-1/pd-l1抑制剂的聚合物纳米载药胶束的制备及在血管损伤后的应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106333926A (zh) * 2015-07-10 2017-01-18 复旦大学 一种稳定性多肽介导跨屏障膜的脑部肿瘤多重靶向递药系统
CN107029239A (zh) * 2016-02-03 2017-08-11 复旦大学 一种多功能靶向分子及其用途
CN108524469A (zh) * 2017-03-06 2018-09-14 复旦大学 一种主动靶向生物膜纳米制剂的制备方法
CN109384850A (zh) * 2017-08-11 2019-02-26 复旦大学 全过程靶向多肽及其在构建肿瘤靶向诊治递药系统中的应用
CN110114367A (zh) * 2016-12-07 2019-08-09 复旦大学 Vap多肽及其在制备靶向诊疗肿瘤药物中的应用
CN110669101A (zh) * 2018-06-14 2020-01-10 复旦大学 特异性靶向乙酰胆碱受体和具有跨生物膜效应的d8多肽及其脑靶向递药系统
CN112641953A (zh) * 2019-10-10 2021-04-13 复旦大学 一种靶向功能分子修饰的抗体复合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002240312A1 (en) * 2001-02-08 2002-08-19 Pankaj Paranjp Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents using polymer conjugates
CN108653236A (zh) * 2017-03-31 2018-10-16 复旦大学 一种生物膜包载药物纳米晶体的制备方法及其用途

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106333926A (zh) * 2015-07-10 2017-01-18 复旦大学 一种稳定性多肽介导跨屏障膜的脑部肿瘤多重靶向递药系统
CN107029239A (zh) * 2016-02-03 2017-08-11 复旦大学 一种多功能靶向分子及其用途
CN110114367A (zh) * 2016-12-07 2019-08-09 复旦大学 Vap多肽及其在制备靶向诊疗肿瘤药物中的应用
CN108524469A (zh) * 2017-03-06 2018-09-14 复旦大学 一种主动靶向生物膜纳米制剂的制备方法
CN109384850A (zh) * 2017-08-11 2019-02-26 复旦大学 全过程靶向多肽及其在构建肿瘤靶向诊治递药系统中的应用
CN110669101A (zh) * 2018-06-14 2020-01-10 复旦大学 特异性靶向乙酰胆碱受体和具有跨生物膜效应的d8多肽及其脑靶向递药系统
CN112641953A (zh) * 2019-10-10 2021-04-13 复旦大学 一种靶向功能分子修饰的抗体复合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
高洪元等: "双级靶向纳米载体在脑肿瘤诊断和治疗方面的应用", 《药学实践杂志》, no. 01, 25 January 2015 (2015-01-25) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115825442A (zh) * 2021-11-23 2023-03-21 中国人民解放军总医院第一医学中心 钙钛矿纳米晶在制备用于肿瘤诊断或治疗的探针中的应用

Also Published As

Publication number Publication date
WO2021147917A1 (fr) 2021-07-29
CN114981310A (zh) 2022-08-30

Similar Documents

Publication Publication Date Title
CN113171468A (zh) 一种全过程靶向分子及其在构建递药系统中的应用
Ma et al. Overcoming multidrug resistance through the GLUT1-mediated and enzyme-triggered mitochondrial targeting conjugate with redox-sensitive paclitaxel release
Wang et al. Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates
Liu et al. Enhanced blood-brain-barrier penetrability and tumor-targeting efficiency by peptide-functionalized poly (amidoamine) dendrimer for the therapy of gliomas
Tiwari et al. Dacarbazine-primed carbon quantum dots coated with breast cancer cell-derived exosomes for improved breast cancer therapy
KR102190093B1 (ko) 난소암을 특이적으로 표적하는 생분해성 양친성 폴리머, 이로부터 제조된 폴리머 배시클 및 용도
US20090035223A1 (en) Biomimetic iron-oxide-containing lipoprotein and related materials
EP3834844A1 (fr) SYSTÈME D'ADMINISTRATION CIBLÉ VERS LE CERVEAU MÉDIÉ PAR UN PEPTIDE COURT ß-AMYLOÏDE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
CN106565825A (zh) 稳定化a7r多肽及其在构建肿瘤靶向诊治递药系统中的用途
Keshavarz et al. CAR, a homing peptide, prolongs pulmonary preferential vasodilation by increasing pulmonary retention and reducing systemic absorption of liposomal fasudil
JP7035050B2 (ja) Ｖａｐポリペプチド及び腫瘍の標的診断及び治療のための薬物の調製におけるその使用
Tian et al. Dextran-doxorubicin prodrug nanoparticles conjugated with CD147 monoclonal antibody for targeted drug delivery in hepatoma therapy
CN109384850A (zh) 全过程靶向多肽及其在构建肿瘤靶向诊治递药系统中的应用
Wang et al. Maleimide as the PEG end-group promotes macrophage-targeted drug delivery of PEGylated nanoparticles in vivo by enhancing interaction with circulating erythrocytes
CN109422801B (zh) 多功能靶向多肽rap及其在制备肿瘤靶向递送系统中的用途
CN109897089B (zh) 一种整合素配体vs多肽及其在制备肿瘤靶向诊治递药系统中的应用
CN108697693B (zh) 用于靶向、成像和治疗前列腺癌的肽共轭的纳米粒子
d’Avanzo et al. C-end rule peptide-guided niosomes for prostate cancer cell targeting
CN111233975A (zh) 可靶向整合素的多肽mn及其在制备肿瘤靶向药物中的应用
Xiao et al. Trojan-like peptide drug conjugate design and construction for application in treatment of triple-negative breast cancer
CN110669101B (zh) 特异性靶向乙酰胆碱受体和具有跨生物膜效应的d8多肽及其脑靶向递药系统
CN108570094A (zh) Ae多肽及其在制备肿瘤靶向诊治递药系统中的用途
CN116410264A (zh) 一种特异性靶向白喉毒素受体的dtx多肽及其应用
CN114796121A (zh) 一种自组装纳米晶药物制剂及其制备方法和用途
JP2021035957A (ja) ポリマーナノ粒子およびその調整のプロセス

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination